Exelixis Inc Current Assets
Exelixis Inc (EXEL) had Current Assets of $1.25 billion as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-05
- 2026-07-03: Assets, Current $1.25B.
- 2026-04-03: Assets, Current $1.21B.
- 2026-01-02: Assets, Current $1.44B.
- 2025-10-03: Assets, Current $1.40B.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-07-03 | $1.25B 10-Q · filed 2026-08-05 | |
| 2026-04-03 | $1.21B 10-Q · filed 2026-05-05 | |
| 2026-01-02 | $1.44B 10-Q · filed 2026-08-05 | |
| 2025-10-03 | $1.40B 10-Q · filed 2025-11-04 | |
| 2025-07-04 | $1.18B 10-Q · filed 2025-07-28 | |
| 2025-04-04 | $1.40B 10-Q · filed 2025-05-13 | |
| 2025-01-03 | $1.47B 10-K · filed 2026-02-10 | |
| 2024-09-27 | $1.55B 10-Q · filed 2024-10-29 | |
| 2024-06-28 | $1.48B 10-Q · filed 2024-08-06 | |
| 2024-03-29 | $1.29B 10-Q · filed 2024-04-30 | |
| 2023-12-29 | $1.32B 10-K · filed 2025-02-11 | |
| 2023-09-29 | $1.44B 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.59B 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $1.64B 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $1.62B 10-K · filed 2024-02-06 | |
| 2022-09-30 | $1.84B 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $1.85B 10-Q · filed 2022-08-09 | |
| 2022-04-01 | $1.84B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.83B 10-K · filed 2023-02-07 | |
| 2021-10-01 | $1.66B 10-Q · filed 2021-11-02 | |
| 2021-07-02 | $1.59B 10-Q · filed 2021-08-05 | |
| 2021-04-02 | $1.43B 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $1.45B 10-K · filed 2022-02-18 | |
| 2020-10-02 | $1.41B 10-Q · filed 2020-11-05 | |
| 2020-07-03 | $1.39B 10-Q · filed 2020-08-06 | |
| 2020-04-03 | $1.14B 10-Q · filed 2020-05-05 | |
| 2020-01-03 | $1.01B 10-K · filed 2021-02-11 | |
| 2019-09-27 | $972.11M 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $957.25M 10-Q · filed 2019-07-31 | |
| 2019-03-29 | $946.30M 10-Q · filed 2019-05-01 | |
| 2018-12-28 | $897.02M 10-K · filed 2020-02-25 | |
| 2018-09-28 | $786.96M 10-Q · filed 2018-11-01 | |
| 2018-06-29 | $686.29M 10-Q · filed 2018-08-01 | |
| 2018-03-30 | $565.68M 10-Q · filed 2018-05-02 | |
| 2017-12-29 | $484.87M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $470.92M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $402.24M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $467.95M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $469.00M 10-Q · filed 2017-11-01 | $470.80M 10-K · filed 2017-02-27 |
| 2016-12-30 | $469.00M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $421.33M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $353.38M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $339.47M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $178.66M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $207.35M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $91.80M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $125.04M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $167.24M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $220.67M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $258.58M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $298.31M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $266.61M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $306.16M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $374.96M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $383.94M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $432.54M 10-K · filed 2014-02-20 | |
| 2012-09-30 | $493.39M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $213.82M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $250.02M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $228.82M 10-K · filed 2013-02-21 | |
| 2011-09-30 | $244.87M 10-Q · filed 2011-10-27 | |
| 2011-06-30 | $283.70M 10-Q · filed 2011-08-04 | |
| 2010-12-31 | $183.49M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |